MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the year ending 2025-12-31, NTLA had -$35,219K decrease in cash & cash equivalents over the period. -$395,865K in free cash flow.

Cash Flow Overview

Change in Cash
-$35,219K
Free Cash flow
-$395,865K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
    • Sales and maturities of marketab...
    • Net proceeds from issuance of co...
    • Stock-based compensation
    • Others
Negative Cash Flow Breakdown
    • Purchases of marketable securiti...
    • General and administrative
    • Operating lease liabilities
    • Others

Cash Flow
2025-12-31
Collaboration revenue
67,671
Research and development
388,861
General and administrative
119,800
Interest income
29,195
Loss from equity method investment
0
Other (income) expense, net
-899
Net loss
-412,694
Depreciation and amortization
9,767
Loss (gain) on disposal of property and equipment
-527
Accelerated amortization/impairment of right-of-use assets
6,156
Stock-based compensation
80,219
Accretion of investment discounts and premiums
5,858
Change in fair value of investments, net
-899
(recognition) deferral of equity method investment intra-entity profit on sales
0
Loss from equity method investment
0
Change in fair value of contingent consideration
0
Accounts receivable
951
Prepaid expenses and other current assets
26,352
Operating lease right-of-use assets
-33,086
Other assets
-2,811
Accounts payable
5,987
Accrued expenses
-5,271
Deferred revenue
-28,111
Operating lease liabilities
-54,951
Net cash used in operating activities
-394,736
Purchases of property and equipment
1,129
Purchases of marketable securities
322,510
Sales and maturities of marketable securities
551,670
Net cash provided by (used in) investing activities
228,031
Net proceeds from issuance of common stock
128,175
Proceeds from options exercised
722
Issuance of shares through employee stock purchase plan
2,589
Net cash provided by financing activities
131,486
Net (decrease) increase in cash, cash equivalents and restricted cash equivalents
-35,219
Cash, cash equivalents and restricted cash equivalents, beginning of period
202,787
Cash, cash equivalents and restricted cash equivalents, end of period
167,568
Unit: Thousand (K) dollars (except for numbers of shares and EPS).

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Sales and maturitiesof marketable...$551,670K Net proceeds fromissuance of common stock$128,175K Issuance of sharesthrough employee stock...$2,589K Proceeds from optionsexercised$722K Net cash provided by(used in) investing...$228,031K Net cash provided byfinancing activities$131,486K Canceled cashflow$323,639K Net (decrease)increase in cash, cash...-$35,219K Canceled cashflow$359,517K Stock-based compensation$80,219K Operating leaseright-of-use assets-$33,086K Depreciation andamortization$9,767K Acceleratedamortization/impairment of right-of-use...$6,156K Accounts payable$5,987K Other assets-$2,811K Change in fair value ofinvestments, net-$899K Loss (gain) ondisposal of property and...-$527K Purchases of marketablesecurities$322,510K Purchases of property andequipment$1,129K Net cash used inoperating activities-$394,736K Canceled cashflow$139,452K Collaboration revenue$67,671K Interest income$29,195K Net loss-$412,694K Canceled cashflow$96,866K Operating leaseliabilities-$54,951K Deferred revenue-$28,111K Prepaid expenses andother current assets$26,352K Accretion of investmentdiscounts and premiums$5,858K Accrued expenses-$5,271K Accounts receivable$951K Research and development$388,861K General andadministrative$119,800K Other (income)expense, net-$899K

Intellia Therapeutics, Inc. (NTLA)

Intellia Therapeutics, Inc. (NTLA)